Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-305 in Relapsed/Refractory Multiple Myeloma
NCT05647512Phase 2Withdrawn
- Sponsor
- LaNova Medicines
- Start
- Jan 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of LM-305 in multiple myeloma (MM), plasma cell disorder (PCD), sponsored by LaNova Medicines. Planned start Jan 2023; status: withdrawn.
02
Drugs
LM-305
03
Conditions
multiple myeloma (MM)plasma cell disorder (PCD)
Beyond the preview
Go deeper on NCT05647512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05647512.